Alder to receive $15m from BMS for start of Phase IIb RA trial
This article was originally published in Scrip
Executive Summary
Alder Biopharmaceuticals is to receive a $15 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase IIb trial of ALD518/BMS-945429, a monoclonal antibody that blocks interleukin-6 (IL-6) in rheumatoid arthritis.